A new study from the University of Vermont’s Robert Larner, M.D. College of Medicine has identified a possible approach to treating impaired brain blood flow and dementias related to vascular dysfunction. The research, published in Proceedings of the National Academy of Sciences on December 22, outlines how restoring a specific phospholipid in the bloodstream may help correct abnormal blood flow in the brain and reduce dementia symptoms.
"This discovery is a huge step forward in our efforts to prevent dementia and neurovascular diseases," said Osama Harraz, Ph.D., assistant professor of pharmacology at Larner College of Medicine and principal investigator for the study. "We are uncovering the complex mechanisms of these devastating conditions, and now we can begin to think about how to translate this biology into therapies."
Dementias such as Alzheimer’s disease affect approximately 50 million people globally, with numbers continuing to rise. These conditions place significant strain on families and healthcare systems.
The research team focused on cerebral blood flow regulation and specifically examined Piezo1, a protein found on cell membranes lining blood vessels that acts as a sensor for frictional forces caused by moving blood. Previous studies have shown that activity levels of Piezo1 are altered in individuals carrying certain gene variations.
The recent findings show that increased activity of Piezo1 is associated with diseases like Alzheimer’s. The scientists investigated PIP₂, a phospholipid present in brain cell membranes crucial for signaling processes within cells. Their experiments revealed that PIP₂ naturally inhibits Piezo1; when PIP₂ levels decrease, Piezo1 becomes overactive, disrupting normal brain blood flow. By reintroducing PIP₂ into their models, researchers were able to suppress Piezo1 activity and restore typical blood circulation patterns.
The results suggest that increasing PIP₂ could be developed as a treatment strategy aimed at improving cerebral blood flow and cognitive function.
Future work will examine exactly how PIP₂ interacts with Piezo1—whether it binds directly or changes membrane properties—and explore how reductions in PIP₂ contribute to ongoing overactivity of Piezo1 seen in disease states. This information will be important for refining potential therapies targeting either PIP₂ or Piezo1 for vascular dementia and related disorders.
